Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Rudresh Jarecha"'
Autor:
Fabien Ricard, Bruce Cheson, Sally Barrington, Judith Trotman, Annette Schmid, Guenther Brueggenwerth, Gilles Salles, Larry Schwartz, Greg Goldmacher, Rudresh Jarecha, Jayant Narang, Florence Broussais, Paul Galette, Min Liu, Surabhi Bajpai, Eric Perlman, Julie Gillis, Ira Smalberg, Pierre Terve, Gudrun Zahlmann, Ron Korn
Publikováno v:
J Nucl Med
Our objective was to provide consensus recommendations from a consortium of academic and industry experts in the field of lymphoma and imaging for consistent application of the Lugano classification. Methods: Consensus was obtained through a series o
Autor:
Fabien Ricard, Sally Barrington, Ron Korn, Guenther Brueggenwerth, Judith Trotman, Bruce Cheson, Gilles Salles, Larry Schwartz, Greg Goldmacher, Rudresh Jarecha, Jayant Narang, Florence Broussais, Paul Galette, Min Liu, Surabhi Bajpai, Eric Perlman, Julie Gillis, Ira Smalberg, Pierre Terve, Gudrun Zahlmann, Annette Schmid
Publikováno v:
Journal of Nuclear Medicine. 64:239-243
Autor:
Jayashree Kalpathy-Cramer, Aria Pezeshk, Rudresh Jarecha, Nicholas Petrick, Maria Athelogou, Marthony Robins, Andrew J. Buckler, Berkman Sahiner, Nancy A. Obuchowski, Ehsan Samei
Publikováno v:
Acad Radiol
RATIONALE AND OBJECTIVES To evaluate a new approach to establish compliance of segmentation tools with the computed tomography volumetry profile of the Quantitative Imaging Biomarker Alliance (QIBA); and determine the statistical exchangeability betw
Autor:
Rudresh Jarecha, Shweta Narang, Manish Sharma, Jayant Narang, Surabhi Bajpai, Ravikanth Mankala
Publikováno v:
Blood. 136:33-34
Background:Mantle cell lymphoma (MCL) is a rare kind of Non-Hodgkin Lymphoma. The incidence of Gastrointestinal (GI) involvement is an important factor in assessing patients and determining the disease burden, although it has not been studied extensi
Autor:
Manish Sharma, Jayant Narang, Surabhi Bajpai, Rudresh Jarecha, Bruce D. Cheson, Christiana Caplan, Gabriele Padrella, Dana Macdonald
Publikováno v:
Blood. 136:34-35
Background: IWCLL 2008 and 2018 criteria require that all lymph nodes/nodal masses be ≤ 15mm in longest diameter (LDi) to be consistent with a CR. Lymph nodes or nodal masses >15mm in the LDi are considered abnormal. However, it has been observed t
Autor:
Ravikanth Mankala, Oliver Bohnsack, Jayant Narang, Rudresh Jarecha, Shweta Narang, Manish Sharma, Surabhi Bajpai, Usha Lalchandani
Publikováno v:
Journal of Clinical Oncology. 39:e19522-e19522
e19522 Background: Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma with over 18,000 new cases diagnosed each year in the United States and approximately 7-8 cases per 100.000 people globally. Hodgkin’s Lymphoma
Autor:
Manish Sharma, Anitha Singareddy, Michael O'Connor, Surabhi Bajpai, Rudresh Jarecha, Jayant Narang
Publikováno v:
Journal of Clinical Oncology. 39:e13557-e13557
e13557 Background: Lung cancer is the leading cause of cancer death in the world including more than 160,000 deaths in the US. The purpose of the study was to determine whether inter reader variability in Sum of Diameters (SOD) of tumor burden has an
Autor:
Jayant Narang, Oliver Bohnsack, Surabhi Bajpai, Anitha Singareddy, Manish Sharma, Rudresh Jarecha
Publikováno v:
Journal of Clinical Oncology. 38:e18058-e18058
e18058 Background: Metastasis is the leading cause of ovarian cancer (OC) related death with more than 70% of OC patients diagnosed with metastasis with five-year survival rates below 45%. OC cells mainly metastasize within the peritoneal cavity at p
Autor:
Rudresh Jarecha, Manish Sharma, Oliver Bohnsack, Rajesh Kaja, Anitha Singareddy, Surabhi Bajpai, Jayant Narang, Michael D O'Connor
Publikováno v:
Journal of Clinical Oncology. 38:e16645-e16645
e16645 Background: Response Evaluation Criteria in Solid Tumors (RECIST) guidelines consider the measurement of treatment response based on tumor shrinkage due to the antitumor activity of cytotoxic drugs. However, tumor response can be misleading wh
Publikováno v:
Journal of Clinical Oncology. 38:4595-4595
4595 Background: mRECIST 2010 criteria for Hepatocellular Carcinoma (HCC) response assessment were focused on a concept of measuring viable tumor tissue showing enhancement in arterial phase of contrast enhanced CT/MRI, whereas RECIST 1.1 focuses mai